In:
Cancer, Wiley, Vol. 119, No. 23 ( 2013-12), p. 4180-4187
Abstract:
The combination of bevacizumab and irinotecan (CPT‐11) was fairly well tolerated in children with recurrent central nervous system tumors. Most severe bevacizumab‐related toxicities were rare, self‐limiting, and manageable.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v119.23
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1